ReportsandReports announce to have
The Gastrointestinal Market Outlook to 2014: (
http://www.reportsandreports.com/market-reports/the-gastrointestinal-market-o
utlook-to-2014-market-dynamics-com/) Market dynamics, competitive landscape,
emerging therapies Market Research Report in its store.
Gastrointestinal disorders are quite diverse affecting different parts of
the alimentary tract such as the pancreas, oropharynx, liver and biliary
system and the alimentary canal. Causes of these disorders vary and could
include genetic anomalies, the effect of certain toxins and drugs,
infections, cancer and often unknown causes. Disorders of the
gastrointestinal tract (GIT) are fairly common and occur in people of all
ages. These disorders take up a significant share of the disease burden in
developed economies and the gravity of the problem is further accentuated by
the difficulty that they pose in effective management. GIT therapy area
consists of some indications that can be treated through pharmacologic
interventions, though significant unmet need still exists. These unmet
medical needs are more common for indications such as irritable bowel
syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC). An
incomplete understanding of the etiologies of these diseases limits their
effective treatment, leading to misguided treatment and misdiagnosis. A
significant fraction of the drugs used in the GIT therapy area are for the
treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease
(GERD). The therapy area overall, however, reflects significant levels of
genericization with R&D efforts drifting towards novel therapies for Crohn's
disease and inflammatory bowel disease (IBD). In several instances though,
the shift could be out of GIT to the faster growing therapy areas such as
oncology, cardiovascular disorders and autoimmune disorders.